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Comparison of adverse events associated with different spacers
used with non-extraﬁne beclometasone dipropionate for
asthma
Simon Wan Yau Ming1, John Haughney2, Dermot Ryan 3,4, Shishir Patel5, Matthias Ochel5, Martina Stagno d’Alcontres1, Susannah
Thornhill1, Janwillem W. H. Kocks 1,6 and David Price 1,2,3
Co-prescription of Aerochamber® spacer with non-extraﬁne beclometasone diproprionate (non-EF BDP) is common but unlicensed.
We report a comparison of inhaled corticosteroid (ICS)-related adverse events between patients co-prescribed Aerochamber
compared to the licensed Volumatic® spacer. We utilised two historical cohorts: questionnaire-based and electronic medical record
(EMR)-based, to assess patient-reported and EMR-recorded adverse events in patients with asthma prescribed non-EF BDP. Marginal
effect estimate (MEE) was calculated to determine non-inferiority of Aerochamber compared to Volumatic in terms of patient-
reported oral thrush and hoarseness with margin of 0.13. Other patient-reported adverse events (sore throat, bruising, weight gain,
and coughing), and EMR-recorded adverse events were also assessed. Rate of patient-reported oral adverse events were non-
inferior in 385 patients prescribed Aerochamber compared to 155 patients prescribed Volumatic (27.7 vs 29.9%; MEE, −0.043; 95%
CI, −0.133 to 0.047). Total patient-reported adverse events did not differ signiﬁcantly between Aerochamber and Volumatic (53.3 vs
49.7% with ≥1 adverse event). The EMR-based study of 1471 matched pairs of subjects did not show signiﬁcantly different number
of EMR-recorded adverse events between Aerochamber and Volumatic (12.5 vs 12.8% with ≥1 adverse events). Co-prescribing
Aerochamber with non-EF BDP does not increase the risk for patient-reported and EMR-recorded ICS-related adverse events
compared to co-prescribing Volumatic.
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INTRODUCTION
Asthma is a heterogeneous disease characterised by chronic
airway inﬂammation that has a substantial impact on quality of life
and healthcare resources. National and international guidelines
recommend inhaled corticosteroids (ICS) as the ﬁrst-line therapy
for treatment of asthma.1,2 ICS treatment has proven to be
efﬁcient at improving lung function, decreasing airway hyperre-
sponsiveness, reducing symptoms, frequency, and severity of
exacerbations, and improving patient quality of life.3–5 Despite
their proven efﬁcacy, ICS can cause both oropharyngeal and
systemic adverse events.6–10
Oropharyngeal adverse events associated with ICS use include
oral candidiasis (oral thrush), hoarseness, dysphonia, pharyngitis,
and cough reﬂex.11–13 Oral thrush is a well-documented adverse
event associated with regular use of ICS in patients with
asthma.6,11,14,15 Approximately 5–10% of patients prescribed ICS
reported adverse events in the oral cavity and pharynx,7,11,12 with
the occurrence of clinically signiﬁcant oropharyngeal candidiasis
as high as 10% in adults6,16,17 and between 1 and 3% in
children.18,19 The reduction of the local immune response,20 or
growth stimulation of Candida albicans21 through an increase in
salivary glucose, are believed to be responsible for the develop-
ment of candidiasis. Multiple factors have been reported to
contribute to the incidence of oral thrush in patients with asthma,
including the type and dose of ICS prescribed, the delivery device
used, and patient adherence to medication instructions.22–24 This
relationship between risk of oral thrush and the type, dose, and
delivery device of ICS has also been observed in chronic
obstructive pulmonary disorder (COPD) patients.6
The use of spacers with pressurised metered dose inhalers
(pMDIs)25 and careful mouth rinsing after using dry powder
inhalers can reduce the risk of oral thrush.18 Spacers are
recommended by asthma treatment guidelines for patients under
the age of 16 years, for those who have problems coordinating
actuation, for those prescribed high-dose ICS, for those at risk of
suffering from local side effects, and for elderly patients.26 The
addition of a spacer to a pMDI has proven to consistently reduce
aerosol velocity and particle size in the aerosol plume, thus
reducing the amount of prescribed therapy deposited in the
oropharyngeal cavity and increasing the amount of active
compound that reaches the lung.27–29 Previous studies have
suggested that spacers used with non-extraﬁne (non-EF) particle
ICS may result in reduced rates of oropharyngeal
candidiasis.28,30,31
Spacers are licensed for use with speciﬁc inhalers. Non-EF
beclometasone dipropionate (BDP) (Clenil® Modulite®) is licensed
for use only with the Volumatic® spacer.32 However, our previous
study found that the Aerochamber® spacer has also been
frequently prescribed, off-label, in conjunction with Clenil
Modulite.33 There is concern that the use of unlicensed spacers
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may result in a greater number of adverse events compared to the
use of licensed spacers. Large spacers, such as the Volumatic
device, have been shown to have more effective drug distribution
compared to smaller spacers, such as the Aerochamber.34,35
However, the ease of use and carriage of the smaller Aerochamber
device make it a more attractive choice for both patients and
prescribers, even if it is not licensed.36 The aim of this study was to
characterise both patient-perceived and electronic medical record
(EMR)-recorded possible ICS-related adverse events in patients
with asthma co-prescribed the licensed Volumatic or the
unlicensed Aerochamber spacer with their non-EF BDP therapy.
This was conducted using two historical cohort studies: a
questionnaire-based study and an EMR-based study for assess-
ment of patient-reported and EMR-recorded adverse events,
respectively.
RESULTS
Study population
The questionnaire-based study consisted of 540 patients who had
questionnaire data, collected for routine practice purpose, of
whom 385 were prescribed the Aerochamber spacer and 155
were prescribed the Volumatic (Fig. 1). The group prescribed
Aerochamber had signiﬁcantly more female patients (65.7 vs
54.8%) and more current smokers (27.2 vs 14.1%) but were
prescribed lower short-acting β2 agonist (SABA) average daily
dosage at baseline (p= 0.003) (Table 1) compared to the
Volumatic group.
A total of 1471 matched pairs were included in the EMR-based
study after 1:1 matching (Fig. 2) with the mean age (SD) of 30
(28.2) years and 54% patients were female (Table 2). More patients
in the Aerochamber group were current smokers (17.9 vs 16.0%).
Patients prescribed the Aerochamber spacer had a higher
percentage predicted peak ﬂow than those prescribed the
Volumatic spacer (59.0 vs 52.5 with ≥80% predicted peak ﬂow
respectively, p= 0.006). However, the number of patients who
experienced at least one severe asthma exacerbation during the 1-
year baseline period was not signiﬁcantly different between the
Aerochamber- and the Volumatic-prescribed groups (24.5 vs 25.6
respectively, p= 0.650).
Patient-reported oral adverse events
Patient-reported oral adverse events (oral thrush or hoarse voice)
were reported in 27.7% patients co-prescribed the unlicensed
Aerochamber compared to 29.9% of patients co-prescribed the
licensed Volumatic spacer. The marginal effect estimate (MEE) was
−0.043 (95% conﬁdence interval (CI), −0.133 to 0.047). As the
upper limit of the 95% CI was less than the pre-deﬁned non-
inferiority margin of 0.13, the Aerochamber was determined to be
non-inferior to the Volumatic spacer in terms of local oral adverse
events (Fig. 3). Non-inferiority was also observed for the outcomes
of oral thrush only (MEE, −0.034; 95% CI, −0.079 to 0.011) and
hoarseness only (MEE, −0.004; 95% CI, −0.091 to 0.083).
Total patient-reported adverse events
There were no signiﬁcant differences in the total number of
overall patient-reported adverse events (sore mouth/throat,
bruising, abnormal weight gain, and cough in addition to oral
thrush and hoarseness) between patients co-prescribed Aero-
chamber and patients co-prescribed Volumatic spacer (53.3 vs
49.7% with ≥1 reported event respectively, p= 0.797) from the
questionnaire-based study.
EMR-recorded adverse events
Of the 1471 patients in both groups prescribed Aerochamber and
Volumatic, 1287 (87.5) and 1283 (87.2%) patients did not have any
EMR-recorded adverse events, respectively. The number of
Fig. 1 Patient ﬂow diagram for the questionnaire-based study (primary objective)
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patients with exactly one recorded adverse event were 169 (11.5)
and 171 (11.6%), respectively, and 15 (1.0) and 17 (1.2%) had 2 or
more adverse events in the Aerochamber and Volumatic groups,
respectively (chi-square p-value= 0.931, Table 3).
Analysed as a continuous variable (counts of adverse events),
the rates of EMR-recorded adverse events were also not
signiﬁcantly different in patients prescribed Aerochamber com-
pared to patients prescribed Volumatic spacer (adjusted rate ratio,
1.28; 95% CI, 0.99 to 1.65).
DISCUSSION
This real-life study in a population of patients with asthma
provides a unique perspective of both patient-reported and EMR-
recorded ICS-related adverse events. Data from both patient
questionnaires and EMR demonstrated that the co-prescription of
the unlicensed Aerochamber spacer with non-extraﬁne beclome-
tasone was not associated with higher patient-reported or EMR-
recorded adverse events than the co-prescription of the licensed
Volumatic device with non-extraﬁne beclometasone.
The combination of the right medication and the optimal
delivery device with the patient’s cognitive and physical abilities
are essential to ensure optimum therapy delivery. The prescription
of devices that are not easily used by patients can result in
incorrect inhaler technique, leading to decreased drug delivery,
poor disease control, and culminating in decreased therapy
adherence.37,38 National and international guidelines offer advice
on which patients should receive speciﬁc therapies.1,26 However,
these are often not strictly followed by healthcare professionals as
patients may be unwilling to carry, or unable to use the device.
Off-label and unlicensed prescriptions may also be given due to
the lack of a licensed therapy available for a patient’s age group.36
Our recent study found that national guidelines for spacer
prescription were not followed for a large proportion of patients
prescribed non-EF BDP.33 Of those patients who were prescribed
spacers, the majority were prescribed the unlicensed Aerocham-
ber spacer (59.0%) followed by the licensed Volumatic device
(18.9%).33
A major concern with unlicensed prescriptions is the potential
for side effects. Several studies have reported an increased
incidence of oral thrush in patients with asthma associated with
ICS dose.22–24,31 To account for this, we adjusted our analysis for
ICS dose in the questionnaire-based study and matched for ICS
daily dose in the EMR-based study. Thus, any difference in ICS-
related adverse events would not have been caused by the ICS
dose. Other reported local side effects of ICS use include
dysphonia, cough reﬂex, and pharyngitis. These are also
considered to be an immediate cause of clinical discomfort,
which in turn reduce patient adherence to therapy, possibly
resulting in a decrease in asthma control.7,11,12 This study clearly
demonstrated that this was not the case for co-prescription of the
unlicensed Aerochamber spacer with non-EF BDP asthma therapy.
In terms of patient-perceived occurrence of oral thrush and
hoarseness, the Aerochamber was non-inferior to the licensed
Volumatic spacer. This was further conﬁrmed by doctor-recorded
data (diagnostic read codes), where patients prescribed the
Aerochamber spacer did not suffer signiﬁcantly more ICS-related
adverse events than those prescribed the Volumatic spacer.
It is very likely that the range and extent of ICS-related adverse
events, as experienced by patients, are underestimated.9,12,39 The
short duration of clinical trials and the stringent inclusion criteria
often limit the quality and quantity of data on adverse events.40,41
Similarly, patient-perceived ICS-associated adverse events may not
be detected during routine clinical practice as patients are often
reluctant to discuss their concerns about medication with their
physicians.42 Discordance and lack of patient–prescriber commu-
nication may cause patients to titrate their medication or self-
medicate, reducing disease control.12 This existing disparity
Table 1. Baseline patient characteristics of questionnaire-based study
Baseline variable Volumatic® (n=
155)
Aerochamber® (N=
385)
P value RCC
Male gender, n (%) 70 (45.2) 132 (34.3) 0.0181 2.1
Age (completed years)
Mean (SD) 42.4 (19.2) 46.7 (15.7) 0.0630 2.9
Median (IQR) 48.0 (32.0) 51.0 (20.0)
Smoking status
Non-smoker, n (%) 108 (72.5) 233 (62.6) 0.0058 0.2
Ex-smoker, n (%) 20 (13.4) 38 (10.2)
Current smoker, n (%) 21 (14.1) 101 (27.2)
Total non-missing (%)a 149 (96.1) 372 (96.6)
BMI (kg/m²)
<18.5, n (%) 15 (9.9) 26 (7.0) 0.4863 0.9
<18.5–24.99, n (%) 53 (35.1) 118 (32.0)
25–29.99, n (%) 43 (28.5) 108 (29.3)
≥30, n (%) 40 (26.5) 117 (31.7)
Total non-missing (%)a 151 (97.4) 369 (95.8)
SABA average daily dosage (μg)
<100, n (%) 26 (16.8) 110 (28.6) 0.0026 2.4
100–200, n (%) 44 (28.4) 109 (28.3)
201–400, n (%) 48 (31.0) 116 (30.1)
>400, n (%) 37 (23.9) 50 (13.0)
ICS average daily prescription (μg BDP equivalent)
<100, n (%) 11 (7.1) 11 (2.9) 0.1447 1.9
100–250, n (%) 71 (45.8) 174 (45.2)
251–500, n (%) 48 (31.0) 131 (34.0)
>500, n (%) 25 (16.1) 69 (17.9)
LABA ≥1 prescription, n
(%)
14 (9.0) 41 (10.6) 0.5741 0.3
LTRA ≥1 prescription, n
(%)
7 (4.5) 11 (2.9) 0.3313 0.4
Eczema diagnosis (1-
year baseline), n (%)
69 (44.5) 139 (36.1) 0.0692 1.0
Rhinitis diagnosis (1-year
baseline), n (%)
51 (32.9) 120 (31.2) 0.6951 0.2
Thrush diagnosis (1-year
baseline), n (%)
11 (7.1) 20 (5.2) 0.3901 0.2
Percentage predicted peak ﬂow
>=80%, n (%) 77 (53.5) 177 (49.6) 0.3037 1.2
50–80%, n (%) 59 (41.0) 168 (47.1)
<=50%, n (%) 8 (5.6) 12 (3.4)
Total non-missing (%)a 144 (92.9) 357 (92.7)
Severe asthma exacerbations in 1-year baselineb
0, n (%) 129 (83.2) 321 (83.4) 0.3908 0.0
1, n (%) 22 (14.2) 45 (11.7)
2, n (%) 2 (1.3) 15 (3.9)
≥ 3, n (%) 2 (1.3) 4 (1.0)
The p values were computed from chi-squared test for categorical
variables, or Mann–Whitney test for continuous variables and variables
presented as both continuous and categorical. Patients were not matched
to preserve statistical power. Summary statistics are presented as counts
and percentages unless stated otherwise. RCC indicating bias potential of
variable when added into the model predicting the outcome
RCC relative change coefﬁcient, IQR interquartile range, BMI body mass
index, SABA short-acting β2 agonist, ICS inhaled corticosteroid, BPD
beclometasone dipropionate, LABA long-acting β2 agonist, LTRA leuko-
triene receptor antagonist
aMissing data present for this variable, percentages for categorical
variables are given as a percentage of the non-missing observations (out
of 155 for Volumatic and 385 for Aerochamber)
bDeﬁned as occurrence of either: (1) asthma-related unscheduled
hospitalisation/accident & emergency (A&E) attendance, (2) an acute
course of oral steroids, or (3) antibiotics prescribed with lower respiratory
consultation
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between doctors and patients, with respect to their approach to
drug-related adverse events, can be tackled via better patient
understanding of their treatment beneﬁts and of potential adverse
effects, and with prescribers trying to better understand the
concerns of patients.43 Previous reports have suggested differ-
ences in patient- versus doctor-reported adverse events,44 and it is
therefore important to integrate self-reported patient question-
naires as a key tool for investigating adverse events. The use of
both patient questionnaires and physician-recorded adverse
events makes this study unique.
Real-world studies assess the results of therapy under condi-
tions of usual care that are not subjected to the selection of
patients through restrictive eligibility criteria as occurs in clinical
trials. Although the Optimum Patient Care Research Database
(OPCRD) is a well-maintained and validated database, we cannot
rule out the possibility of inaccurate or missing data. The
outcomes were studied over 3 full years for the cohort study to
balance seasonal inﬂuences on outcome measures. However, the
real-life nature of this study also means that although spacer
prescriptions were identiﬁed, it is not guaranteed that the
prescriptions were ﬁlled or that the spacers were used. A
limitation inherent to observational studies is the possibility of
unrecognised confounding factors or inﬂuences in prescribing
that were not accounted for such as inhaler technique. Lastly, only
read-coded adverse events would have been detected in the EMR-
based study. This is however unlikely to be unbalanced between
either spacer arms and thus is not expected to signiﬁcantly affect
the ﬁnding of this study.
The current study focused on the adverse events of spacer co-
prescription with non-extraﬁne beclometasone prescription for
asthma. More recent devices are able to generate ICS aerosol as
extraﬁne particles which has been previously reported by various
studies to have comparable to superior efﬁcacy and safety
compared to non-extraﬁne formulation.15,45 Further studies will
be required to extend the ﬁnding of this study to spacer use with
ICS delivered as extraﬁne particles.
In conclusion, this study found that co-prescription of the
unlicensed Aerochamber spacer with non-extraﬁne beclometa-
sone dipropionate therapy for asthma did not increase the risk of
developing patient-reported or EMR-recorded ICS-related adverse
events, as compared to co-prescription of the licensed Volumatic
device.
METHODS
Data source
The study utilised a large UK primary care database, the OPCRD (www.
opcrd.co.uk).46 The OPCRD currently comprises fully anonymous, long-
itudinal medical records for over 4.5 million patients from over 600 primary
care practices across the United Kingdom. The OPCRD contains two types
of data: (1) routinely recorded clinical data and (2) questionnaire data
(collected as part of routine patient data collection) from over 55,700
patients with respiratory conditions. This enables real-life studies to draw
on information from both perspectives, ensuring a more complete answer
to the questions posed. The OPCRD is approved by the Health Research
Authority of the UK NHS for clinical research use (Research Ethics
Committee (REC) reference: 15/EM/0150). Records contain complete
prescribing, coded diagnostic, and clinical information, as well as
information on tests requested, laboratory results, and referrals made at
or following on from each consultation.47
Fig. 2 Patient ﬂow diagram for the electronic medical record (EMR)-based study (secondary objective)
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Study design
This was a post-authorisation safety study utilising two separate historical
study designs to achieve the objectives. The ﬁrst was a historical study
involving routine questionnaire data stored in the OPRCD to compare
patient-reported ICS-related adverse events for asthma patients prescribed
non-EF BDP with either a Volumatic or an Aerochamber spacer. This
consisted of a 1-year baseline period for patient characterisation,
concluding at the index date, deﬁned as the date of return of the asthma
questionnaire.
The second design was a historical EMR-based study to compare
physician-recorded outcomes, composed of a 1-year baseline period for
characterisation and matching, followed by a 3-year outcome period for
detection of adverse events. The index date was deﬁned as the date of ﬁrst
spacer prescription (Volumatic or Aerochamber).
The study protocol was overseen by an independent steering committee
and registered with the European Network of Centers for Pharmacoepi-
demiology and Pharmacovigilance (trial registration number EUPAS13194)
and the Anonymous Data Ethics Protocols and Transparency (ADEPT)
committee (Ref: ADEPT0517) prior to data extraction.
Patients
For the questionnaire-based study, eligible patients were aged ≤65 years,
with a Read code (clinical coding system within UK’s primary care)
conﬁrmed asthma diagnosis. They received ≥2 separate non-EF BDP (Clenil
Modulite) prescriptions with one prescription for a spacer (Volumatic or
Aerochamber) during the baseline year prior to the date of the
questionnaire and had 2 years of continuous practice data (comprising
≥1 year of data prior to the questionnaire).
Eligible patients of the EMR-based study were aged ≤65 years, with a
Read code conﬁrmed asthma diagnosis. They received ≥2 separate non-EF
BDP (Clenil Modulite) prescriptions in the baseline year and another ≥2
prescriptions in 1 year after index. They were prescribed either Volumatic
or Aerochamber spacer at the index date and had 4 years of continuous
practice data (comprising ≥1 year of baseline data and 3 years of outcome
data).
Patients were excluded from both studies if they received prescriptions
for different ICS or ﬁxed-dose combination) ICS/LABA (long-acting β-
agonist) therapy or were ever prescribed both Volumatic and Aerochamber
spacers (Supplementary Table 1, Supplementary Table 2, Figs. 1 and 2).
Outcome measures
The primary objective was to determine non-inferiority of non-EF BDP co-
prescribed with an Aerochamber spacer, compared to the Volumatic
spacer, in terms of the frequency of patient-reported oral thrush or
hoarseness via the asthma questionnaire over a single year. Other adverse
events captured via the questionnaire included sore mouth/throat,
bruising, abnormal weight gain, and cough.
The secondary objective was to compare EMR outcomes for non-EF BDP
co-prescribed with either the Volumatic or the Aerochamber spacer in the
EMR-based study. Read codes for adverse events to non-EF BDP, as deﬁned
in the product information sheet32 (oral thrush, adrenal suppression
diagnosis, osteoporosis/osteopenia, anxiety/depression, cataracts, and
glaucoma) over a 3-year period were extracted from the OPCRD.
Adjustment and matching
For the questionnaire-based study, patients in each spacer group were
compared following adjustment for variables selected from those with the
highest relative change in coefﬁcient. The ﬁnal variables used for
adjustment were gender, ICS average dose, and smoking status, selected
based on clinical judgement and baseline balance. Matching was not
conducted for the questionnaire-based study to preserve statistical power
due to sample size.
For the EMR-based study, exact matching for categorical variables and
matching within a maximum calliper for numeric variables were used to
match patients using 1:1 nearest neighbour matching, without replace-
ment. Matching variables such as demographic data, disease co-morbidity,
and indicators of disease severity were considered for selection using a
combination of baseline data analysis and predictive modelling of the
baseline data in relation to the outcome variable (independent of
treatment group). The ﬁnal criteria settled on a mix of direct and
propensity score matching (Supplementary Table 3).
Statistical analysis
The study was powered using the occurrence of oral thrush as the
representative adverse event. The occurrence of adverse events (34%) was
based on the oropharyngeal adverse events in users of ICS in a real-life
setting reported in the literature.9,48 With sample sizes of at least 293 and
147, a two-group large-sample normal approximation test of proportions
with a one-sided 0.025 signiﬁcance level would have 80% power to reject
Table 2. Matched baseline patient characteristics of EMR-based study
Baseline variable Volumatic® (n=
1471)
Aerochamber® (N= 1471) P value
Male gendera, n (%) 678 (46.1) 678 (46.1) 1.0000
Age (completed years)a
Mean (SD) 30.0 (28.2) 30.0 (28.2) 0.9079
Median (IQR) 11.0 (52.0) 11.0 (53.0)
Smoking status
Non-smoker, n (%) 1058 (78.8) 980 (74.4) 0.0064
Ex-smoker, n (%) 69 (5.1) 102 (7.7)
Current smoker, n (%) 215 (16.0) 236 (17.9)
Total non-missing (%)b 1342 (91.2) 1318 (89.6)
BMI (kg/m²)
<18.5, n (%) 350 (37.4) 363 (38.1) 0.5190
18.5−24.99, n (%) 121 (12.9) 129 (13.6)
25–29.99, n (%) 122 (13.0) 103 (10.8)
≥30, n (%) 342 (36.6) 357 (37.5)
Total non-missing (%)b 935 (63.6) 952 (64.7)
SABA average daily dosage (μg)
<100, n (%) 216 (14.7) 210 (14.3) 0.5738
100–200, n (%) 374 (25.4) 393 (26.7)
201–400, n (%) 514 (34.9) 530 (36.0)
>400, n (%) 367 (24.9) 338 (23.0)
ICS average daily prescription (μg BDP equivalent)a
<100, n (%) 208 (14.1) 208 (14.1) 1.0000
100-250, n (%) 617 (41.9) 617 (41.9)
251–500, n (%) 351 (23.9) 351 (23.9)
>500, n (%) 295 (20.1) 295 (20.1)
LABA ≥1 prescription, n (%) 215 (14.6) 223 (15.2) 0.6786
LTRA ≥1 prescription, n (%) 111 (7.5) 122 (8.3) 0.4527
Eczema diagnosis (1-year
baseline), n (%)
669 (45.5) 613 (41.7) 0.0373
Rhinitis diagnosis (1-year
baseline), n (%)
296 (20.1) 320 (21.8) 0.2768
Thrush diagnosis (1-year
baseline), n (%)
77 (5.2) 70 (4.8) 0.5536
Percentage predicted peak ﬂow
>=80% 576 (52.5) 641 (59.0) 0.0064
50–80% 447 (40.7) 372 (34.2)
<=50% 72 (6.6) 74 (6.8)
Total non-missing (%)b 1099 (74.8) 1,087 (73.9)
Severe asthma exacerbations in 1-year baselinec
0, n (%) 1095 (74.4) 1111 (75.5) 0.6499
1, n (%) 245 (16.7) 248 (16.9)
2, n (%) 83 (5.6) 72 (4.9)
≥3, n (%) 48 (3.3) 40 (2.7)
The p values were computed from chi-squared test for categorical
variables, or Mann–Whitney test for continuous variables and variables
presented as both continuous and categorical. Summary statistics were
presented as counts and percentages unless stated otherwise
EMR electronic medical record, IQR interquartile range, BMI body mass
index, SABA short-acting β2 agonist, ICS inhaled corticosteroid, BPD
beclometasone dipropionate, LABA long-acting β2 agonist, LTRA leuko-
triene receptor antagonist
aMatching variables
bMissing data present for this variable, percentages for categorical
variables are given as a percentage of the non-missing observations (out
of 1471 patients in both groups)
cDeﬁned as occurrence of either: (1) asthma-related unscheduled
hospitalisation/accident & emergency (A&E) attendance, (2) an acute
course of oral steroids, or (3) antibiotics prescribed with lower respiratory
consultation
S.W.Y. Ming et al.
5
Published in partnership with Primary Care Respiratory Society UK npj Primary Care Respiratory Medicine (2019)     3 
the null hypothesis that the test and the standard are not equivalent (the
difference in proportions, pT−pS, is 0.130 or farther from zero in the same
direction).
All analyses were carried out using IBM SPSS Statistics version 21 (IBM
SPSS Statistics, Feltham, Middlesex, UK), SAS version 9.3 (SAS Institute,
Marlow, Buckinghamshire, UK), and Microsoft Ofﬁce Excel 2013 (Microsoft
Corp., Redmond, Washington, USA). Forest Plot was generated with
DistillerSR Forest Plot Generator from Evidence Partners.
MEE of spacer type (Aerochamber or Volumatic) on the reported oral
thrush/hoarse voice incidence was calculated to determine non-inferiority
in the primary outcome analysis. The MEE was calculated from predictions
of the model at ﬁxed values of the covariates and averaging over the
remaining covariates to obtain an interval where the result was likely to lie.
Chi-square test was utilised to obtain the odds ratio of adverse events
identiﬁed from the EMR (EMR-recorder adverse events). Poisson regression
was utilised to calculate the rate ratio of EMR-recorded adverse events,
adjusted for osteoporosis and anxiety/depression diagnosis. The p value of
<0.05 was considered statistically signiﬁcant.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this article.
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